TMBR
AMEXTimber Pharmaceuticals Inc.
Latest news
25 items- SECTimber Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
- SECTimber Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
- SECTimber Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
- NEWSTimber Pharmaceuticals Reveals Commencement Of NYSE American Delisting Proceedings: Common Stock Expected To Begin Trading On OTC Market
- PRTimber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketWARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the staff of NYSE Regulation (the "NYSE Regulation") has determined to immediately suspend trading in the Company's common stock from NYSE American, LLC (the "NYSE American"). As previously disclosed, the NYSE Regulation notified Timber on November 21, 2023 that, as a result of the voluntary bankruptcy petitions filed under Chapter 11 of the United States Bankruptcy Code by the Company and certain of its
- SECSEC Form 25-NSE filed by Timber Pharmaceuticals Inc.25-NSE - Timber Pharmaceuticals, Inc. (0001504167) (Subject)
- SECTimber Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
- NEWSTimber Pharmaceuticals Receives Court Approval Of All "First Day" Motions To Support Business Operations & Discloses Communication From NYSE American
- PRTimber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE AmericanWARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-in-possession ("Timber" or the "Company"), today announced that all "first day" motions related to the Company's voluntary Chapter 11 petitions for reorganization filed on November 17, 2023, were approved on an interim basis by the U.S. Bankruptcy Court for the District of Delaware. At the hearing, among other things, the Court approved an initial $3.0 million in interim funding pursuant to a debt
- SECTimber Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Termination of a Material Definitive Agreement, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
- NEWSTimber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy; Timber Pharmaceuticals, Inc. Lists Both Assets And Liabilities In Range Of $1M-$10M- Court Filing
- NEWSTimber Pharmaceuticals Says Proposal To Approve Merger Agreement Was Not Approved By A Majority Of Outstanding Shares Of Common Stock Entitled To Vote; Held Special Meeting To Vote On Matters Like Adopt Plan Of Merger With Leo US, Leo Spiny Merger Sub- SEC Filing
- SECTimber Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
- NEWSTimber Pharmaceuticals Shares Halted, News Pending
- SECSEC Form NT 10-Q filed by Timber Pharmaceuticals Inc.NT 10-Q - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
- SECSEC Form DEFA14A filed by Timber Pharmaceuticals Inc.DEFA14A - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
- SECSEC Form 425 filed by Timber Pharmaceuticals Inc.425 - Timber Pharmaceuticals, Inc. (0001504167) (Subject)
- SECTimber Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
- SECTimber Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
- SECSEC Form 425 filed by Timber Pharmaceuticals Inc.425 - Timber Pharmaceuticals, Inc. (0001504167) (Subject)
- NEWSTimber Pharmaceuticals Announces NYSE Acceptance Of Plan To Regain Listing Compliance
- PRTimber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing ComplianceWARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the NYSE American LLC (the "NYSE American") has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. As previously disclosed, on June 28, 2023, the Company received written notice from the NYSE American that the Company was not in compliance with Sections 1003(a)(i)
- SECTimber Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
- SECSEC Form DEFM14A filed by Timber Pharmaceuticals Inc.DEFM14A - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
- SECSEC Form PRER14A filed by Timber Pharmaceuticals Inc.PRER14A - Timber Pharmaceuticals, Inc. (0001504167) (Filer)
TMBR FAQ
6 questionsWhat does Timber Pharmaceuticals Inc. do?
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical dermatology company, focused on the development and commercialization of treatments for orphan dermatologic diseases. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.Where does TMBR stock trade?
Timber Pharmaceuticals Inc. (TMBR) is listed on AMEX.What sector and industry is TMBR in?
Timber Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Timber Pharmaceuticals Inc. go public?
Timber Pharmaceuticals Inc. (TMBR) completed its IPO in 2015.What companies are similar to TMBR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TMBR side-by-side with any of them on Quantisnow.How can I track TMBR on Quantisnow?
Quantisnow aggregates Timber Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TMBR to receive live email and push alerts on every new disclosure.